An international research agenda for clozapine-resistant schizophrenia

Jurjen J. Luykx; Jairo M. Gonzalez-Diaz; Ta Wei Guu; Marte Z. van der Horst; Edwin van Dellen; Marco P. Boks; Sinan Guloksuz; Lynn E. DeLisi; Iris E. Sommer; Russel Cummins; David Shiers; Ahmed Mhalla; Zohra Chadly; Sherry K.W. Chan; Robert O. Cotes; Shun Takahashi; Michael E. Benros; Elias Wagner; Christoph U. Correll; Alkomiet Hasan; Dan Siskind; Dominique Endres; James MacCabe; Jari Tiihonen

doi:10.1016/S2215-0366(23)00109-8

An international research agenda for clozapine-resistant schizophrenia

Jurjen J. Luykx, Jairo M. Gonzalez-Diaz, Ta Wei Guu, Marte Z. van der Horst, Edwin van Dellen, Marco P. Boks, Sinan Guloksuz, Lynn E. DeLisi, Iris E. Sommer, Russel Cummins, David Shiers, Ahmed Mhalla, Zohra Chadly, Sherry K.W. Chan, Robert O. Cotes, Shun Takahashi, Michael E. Benros, Elias Wagner, Christoph U. Correll, Alkomiet HasanDan Siskind, Dominique Endres, James MacCabe, Jari Tiihonen

Producción científica: Contribución a una revista › Artículo de revisión › revisión exhaustiva

8 Citas (Scopus)

Resumen

Los síntomas resistentes al tratamiento se dan en aproximadamente un tercio de los pacientes con esquizofrenia y se asocian a una reducción sustancial de su calidad de vida. El desarrollo de nuevas opciones terapéuticas para la esquizofrenia resistente a la clozapina constituye una necesidad crucial e insatisfecha en psiquiatría. Además, no se dispone de una visión general de las vías de investigación pasadas y futuras para optimizar la detección precoz, el diagnóstico y el tratamiento de la esquizofrenia resistente a la clozapina. En esta Política Sanitaria, discutimos los retos actuales asociados con la esquizofrenia resistente a la clozapina a los que se enfrentan los pacientes y los profesionales sanitarios de todo el mundo para mejorar la comprensión de esta enfermedad. A continuación, revisamos varias directrices sobre la clozapina, las pruebas diagnósticas y las opciones de tratamiento para la esquizofrenia resistente a la clozapina, y los enfoques de investigación aplicados actualmente en la esquizofrenia resistente a la clozapina. También sugerimos metodologías y objetivos para futuras investigaciones, divididas en ensayos de campo innovadores orientados a la nosología (p. ej., examinar la estadificación dimensional de los síntomas), enfoques traslacionales (p. ej., genética), investigación epidemiológica (p. ej., estudios del mundo real) y estudios de intervención (p. ej., diseños de ensayos no tradicionales que incorporen experiencias vividas y perspectivas de los cuidadores).

Idioma original	Inglés estadounidense
Páginas (desde-hasta)	644-652
Número de páginas	9
Publicación	The Lancet Psychiatry
Volumen	10
N.º	8
DOI	https://doi.org/10.1016/S2215-0366(23)00109-8
Estado	Publicada - ago. 2023

Áreas temáticas de ASJC Scopus

Psiquiatría y salud mental
Psiquiatría biológica

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Acceder al documento

10.1016/S2215-0366(23)00109-8

Otros archivos y enlaces

Citar esto

Luykx, J. J., Gonzalez-Diaz, J. M., Guu, T. W., van der Horst, M. Z., van Dellen, E., Boks, M. P., Guloksuz, S., DeLisi, L. E., Sommer, I. E., Cummins, R., Shiers, D., Mhalla, A., Chadly, Z., Chan, S. K. W., Cotes, R. O., Takahashi, S., Benros, M. E., Wagner, E., Correll, C. U., ... Tiihonen, J. (2023). An international research agenda for clozapine-resistant schizophrenia. The Lancet Psychiatry, 10(8), 644-652. https://doi.org/10.1016/S2215-0366(23)00109-8

@article{7a1ba30f734a4aac9efdc4cfa1faeb1c,

title = "An international research agenda for clozapine-resistant schizophrenia",

abstract = "Treatment-resistant symptoms occur in about a third of patients with schizophrenia and are associated with a substantial reduction in their quality of life. The development of new treatment options for clozapine-resistant schizophrenia constitutes a crucial, unmet need in psychiatry. Additionally, an overview of past and possible future research avenues to optimise the early detection, diagnosis, and management of clozapine-resistant schizophrenia is unavailable. In this Health Policy, we discuss the ongoing challenges associated with clozapine-resistant schizophrenia faced by patients and health-care providers worldwide to improve the understanding of this condition. We then revisit several clozapine guidelines, the diagnostic tests and treatment options for clozapine-resistant schizophrenia, and currently applied research approaches in clozapine-resistant schizophrenia. We also suggest methodologies and targets for future research, divided into innovative nosology-oriented field trials (eg, examining dimensional symptom staging), translational approaches (eg, genetics), epidemiological research (eg, real-world studies), and interventional studies (eg, non-traditional trial designs incorporating lived experiences and caregivers' perspectives). Finally, we note that low-income and middle-income countries are under-represented in studies on clozapine-resistant schizophrenia and propose an agenda to guide multinational research on the cause and treatment of clozapine-resistant schizophrenia. We hope that this research agenda will empower better global representation of patients living with clozapine-resistant schizophrenia and ultimately improve their functional outcomes and quality of life.",

author = "Luykx, {Jurjen J.} and Gonzalez-Diaz, {Jairo M.} and Guu, {Ta Wei} and {van der Horst}, {Marte Z.} and {van Dellen}, Edwin and Boks, {Marco P.} and Sinan Guloksuz and DeLisi, {Lynn E.} and Sommer, {Iris E.} and Russel Cummins and David Shiers and Ahmed Mhalla and Zohra Chadly and Chan, {Sherry K.W.} and Cotes, {Robert O.} and Shun Takahashi and Benros, {Michael E.} and Elias Wagner and Correll, {Christoph U.} and Alkomiet Hasan and Dan Siskind and Dominique Endres and James MacCabe and Jari Tiihonen",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier Ltd",

year = "2023",

month = aug,

doi = "10.1016/S2215-0366(23)00109-8",

language = "English (US)",

volume = "10",

pages = "644--652",

journal = "The Lancet Psychiatry",

issn = "2215-0366",

publisher = "Elsevier Limited",

number = "8",

}

Luykx, JJ, Gonzalez-Diaz, JM, Guu, TW, van der Horst, MZ, van Dellen, E, Boks, MP, Guloksuz, S, DeLisi, LE, Sommer, IE, Cummins, R, Shiers, D, Mhalla, A, Chadly, Z, Chan, SKW, Cotes, RO, Takahashi, S, Benros, ME, Wagner, E, Correll, CU, Hasan, A, Siskind, D, Endres, D, MacCabe, J & Tiihonen, J 2023, 'An international research agenda for clozapine-resistant schizophrenia', The Lancet Psychiatry, vol. 10, n.º 8, pp. 644-652. https://doi.org/10.1016/S2215-0366(23)00109-8

TY - JOUR

T1 - An international research agenda for clozapine-resistant schizophrenia

AU - Luykx, Jurjen J.

AU - Gonzalez-Diaz, Jairo M.

AU - Guu, Ta Wei

AU - van der Horst, Marte Z.

AU - van Dellen, Edwin

AU - Boks, Marco P.

AU - Guloksuz, Sinan

AU - DeLisi, Lynn E.

AU - Sommer, Iris E.

AU - Cummins, Russel

AU - Shiers, David

AU - Mhalla, Ahmed

AU - Chadly, Zohra

AU - Chan, Sherry K.W.

AU - Cotes, Robert O.

AU - Takahashi, Shun

AU - Benros, Michael E.

AU - Wagner, Elias

AU - Correll, Christoph U.

AU - Hasan, Alkomiet

AU - Siskind, Dan

AU - Endres, Dominique

AU - MacCabe, James

AU - Tiihonen, Jari

PY - 2023/8

Y1 - 2023/8

N2 - Treatment-resistant symptoms occur in about a third of patients with schizophrenia and are associated with a substantial reduction in their quality of life. The development of new treatment options for clozapine-resistant schizophrenia constitutes a crucial, unmet need in psychiatry. Additionally, an overview of past and possible future research avenues to optimise the early detection, diagnosis, and management of clozapine-resistant schizophrenia is unavailable. In this Health Policy, we discuss the ongoing challenges associated with clozapine-resistant schizophrenia faced by patients and health-care providers worldwide to improve the understanding of this condition. We then revisit several clozapine guidelines, the diagnostic tests and treatment options for clozapine-resistant schizophrenia, and currently applied research approaches in clozapine-resistant schizophrenia. We also suggest methodologies and targets for future research, divided into innovative nosology-oriented field trials (eg, examining dimensional symptom staging), translational approaches (eg, genetics), epidemiological research (eg, real-world studies), and interventional studies (eg, non-traditional trial designs incorporating lived experiences and caregivers' perspectives). Finally, we note that low-income and middle-income countries are under-represented in studies on clozapine-resistant schizophrenia and propose an agenda to guide multinational research on the cause and treatment of clozapine-resistant schizophrenia. We hope that this research agenda will empower better global representation of patients living with clozapine-resistant schizophrenia and ultimately improve their functional outcomes and quality of life.

AB - Treatment-resistant symptoms occur in about a third of patients with schizophrenia and are associated with a substantial reduction in their quality of life. The development of new treatment options for clozapine-resistant schizophrenia constitutes a crucial, unmet need in psychiatry. Additionally, an overview of past and possible future research avenues to optimise the early detection, diagnosis, and management of clozapine-resistant schizophrenia is unavailable. In this Health Policy, we discuss the ongoing challenges associated with clozapine-resistant schizophrenia faced by patients and health-care providers worldwide to improve the understanding of this condition. We then revisit several clozapine guidelines, the diagnostic tests and treatment options for clozapine-resistant schizophrenia, and currently applied research approaches in clozapine-resistant schizophrenia. We also suggest methodologies and targets for future research, divided into innovative nosology-oriented field trials (eg, examining dimensional symptom staging), translational approaches (eg, genetics), epidemiological research (eg, real-world studies), and interventional studies (eg, non-traditional trial designs incorporating lived experiences and caregivers' perspectives). Finally, we note that low-income and middle-income countries are under-represented in studies on clozapine-resistant schizophrenia and propose an agenda to guide multinational research on the cause and treatment of clozapine-resistant schizophrenia. We hope that this research agenda will empower better global representation of patients living with clozapine-resistant schizophrenia and ultimately improve their functional outcomes and quality of life.

UR - http://www.scopus.com/inward/record.url?scp=85165341293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85165341293&partnerID=8YFLogxK

U2 - 10.1016/S2215-0366(23)00109-8

DO - 10.1016/S2215-0366(23)00109-8

M3 - Review article

C2 - 37329895

AN - SCOPUS:85165341293

SN - 2215-0366

VL - 10

SP - 644

EP - 652

JO - The Lancet Psychiatry

JF - The Lancet Psychiatry

IS - 8

ER -

An international research agenda for clozapine-resistant schizophrenia

Resumen

Áreas temáticas de ASJC Scopus

ODS de las Naciones Unidas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto